An overview of reports about the **Laboratory Corporation of America Holdings (LH)** reveals several significant developments. The company is predominantly highlighting its **enhanced EPS outlook** amidst a mixed quarter and a **improved revenue outlook for 2026** alongside certain **buybacks** schemes. This has garnered their shares a lot of attention, with firms, institutional investors, and individuals such as **Legal & General Group Plc** and **Russell Investments Group Ltd.** buying substantial numbers of shares.There's been a series of share transactions with both large purchases and sell-offs from notable groups and insiders, such as **Elo Mutual Pension Insurance Co**, **2Xideas AG**, and **Jefferies Financial Group Inc**. LH has also observed key personnel changes including the introduction of **Victor Bulto** to the board of directors, followed by an insider sale of shares by the likes of **Adam Schechter**. It announced a **dividend of $0.72** and has also completed the **acquisition of select assets** of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses. Its plans to **expand collaboration with PathAI** and deploying an FDA-cleared digital pathology platform nationwide also stand out.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 05 Nov 2014 08:00:00 GMT to Sat, 14 Mar 2026 14:07:32 GMT -
Rating 7
- Innovation 3
- Information 6
- Rumor -4
